Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 26, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the Company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 2,300,000 ordinary shares of 25 pence each.
- Repurchase Price: 1,050.51 pence per share.
- Treasury Shares Held: 504,194,158 shares (representing 9.30% of total voting rights).
- Shares in Issue: 5,420,033,050 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the Company's share capital through the cancellation of 2,300,000 repurchased shares. Consequently, the total number of shares in issue stands at 5,420,033,050, which serves as the denominator for calculating shareholder notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the updated total number of shares in issue (5,420,033,050) for calculating disclosure thresholds.
- Confirm the current percentage of Treasury shares held by the Company (9.30% of total voting rights).
- Review the Annual General Meeting minutes from May 23, 2007, to understand the full scope of the share buyback authority utilized.